Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

Abstract Background V domain Immunoglobulin suppressor of T cell activation (VISTA) has been proved to be a novel immune checkpoint molecule that positively regulates T cell infiltration in several malignancies. However, the clinical impact of VISTA on muscle-invasive bladder cancer (MIBC) patients...

Full description

Bibliographic Details
Main Authors: Wandi Li, Zhaopei Liu, Kaifeng Jin, Fei Shao, Han Zeng, Yiwei Wang, Yu Zhu, Le Xu, Zewei Wang, Yuan Chang, Weijuan Zhang
Format: Article
Language:English
Published: BMC 2023-07-01
Series:BMC Cancer
Subjects:
V domain immunoglobulin suppressor of T cell activation
Muscle-invasive bladder cancer
Adjuvant chemotherapy
Immunotherapy
Tumor microenvironment
Online Access:https://doi.org/10.1186/s12885-023-11157-x

Internet

https://doi.org/10.1186/s12885-023-11157-x

Similar Items